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P34 YOUTH INVOLVEMENT – AN OPTIMAL TECHNIQUE TO
ERADICATE CANCER
M.F. Mkhize. Umvithi Youth Development Consultants, KwaZulu
Natal, South Africa
Background: Evidence that any delay in providing information
results in lack of treatment or admission, which might result in
death or irreversible harm to an individual, constitutes an emer-
gency. Involving youth in the process could help avoid an unnec-
essary lack of information, and might contribute to the
sustainable legacy of fighting cancer. Youth-development pro-
grammes and initiatives associated with awareness, education,
and eradication of cancer could decrease unnecessary deaths
caused by cancer. Ongoing youth-development projects and part-
nership campaigns could improve health awareness.
Methods: Analysis of 500 young people involved in a Rural
Youth Health-Development programme (RYHD) conducted by
Umvithi Youth Development and Department of Health in KwaZ-
ulu, Natal, showed an improved ability to care, teach, and prevent
cancer. Through the RYHD, 2500 community members underwent
training and tests to recognise symptoms, and others were diag-
nosed with cancer and related diseases that they were not aware
of.
Findings: As a result of the RYHD, many individuals took
positive action and full responsibility to decrease cancer risk,
such as quitting smoking, eating healthy food, and exercising
regularly.
Interpretation: Utilising youth for information distribution and
involvement in the fight against cancer could propel communities
towards sustainable improvement in health, and enhances
the ability of individuals to take responsibility for their own
health. Young people are founders and initiators of projects,
groups, and organisations; they are lobbyists, decision-makers,
and are a key element for building a successful and growing
community.
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Background: Many lung-cancer studies have shown that female
patients without a history of smoking and of Asian origin have a
good response to tyrosine-kinase inhibitors (TKIs). Epidermal
growth-factor receptor (EGFR) mutations are prevalent in these
patients, which explains the promising response to TKIs. How-
ever, prevalence of mutations in the EGFR gene and response to
TKIs in Indonesian patients with lung cancer has not been stud-
ied. We have begun preliminary work to collect cytological sam-
ples from 14 patients, to assess the prevalence of EGFR
mutations and related clinicopathological parameters such as
sex, age, stage, and response to TKIs.
Methods: Cytological slides were examined by pathologists
and tumour cells were microdissected, to isolate total DNA,
and sent to a certified reference laboratory in Jakarta. Direct
DNA sequencing was done against exon 19 and 21 of the EGFR
gene, which are the most frequent sites of mutation according
to literature.
Findings: EGFR mutations were found in 50% of patients
(n = 14); female patients had a higher frequency than male
patients (71% [5 of 7] vs. 29% [2 of 7]). Deletion of exon 19 was
more common than substitution mutations in exon 21, which
contributed up to 71% and 29% to the overall mutation rate,
respectively. EGFR mutation was not associated with age or other
clinicopathological parameters. Response to TKIs in patients with
and without EGFR mutations is currently being investigated.
Interpretation: EGFR mutations are more prevalent in Indone-
sian women than in men, and deletion of exon 19 being the most
common mutation type. The preliminary response of patients to
TKIs is being evaluated. Large prospective studies are needed to
evaluate the response to TKIs among Indonesians with EGFR
mutations.
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Background: Bladder cancer is among the five most common
malignancies worldwide, and recurrence of non-invasive
tumours makes it one of the most prevalent cancers. Cystoscopy
in conjunction with urine cytology is the gold standard for detec-
tion of bladder cancer; however, cystoscopy is invasive and
expensive, with low accuracy for high-grade disease. Urine cytol-
ogy has low sensitivity for detection of low-grade bladder cancer.
The aim of study was to quantitate cytokeratin 20 (CK20) mRNA
expression in exfoliated cells of urine in patients with transi-
tional-cell carcinoma (TCC), by use of SYBR Green real-time
PCR, which may be used as a non-invasive tool for follow-up of
patients with bladder cancer.
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Methods: Urine was collected from 78 bladder-cancer patients
during follow-up, from 20 patients with benign urological disease,
and from 20 healthy volunteers. RNAwas isolated from exfoliated
cells in urine by use of an RNA purification kit, and real-time PCR
was performed with specific primers for the amplification of
CK20, a marker for TCC urothelium.
Findings: A strong correlation was found between tumour
grade and expression of CK20 in urine. All patients with grade
III and IV tumours showed positive CK20 expression in the exfo-
liated cells, with 100% sensitivity. The sensitivity for lower grades
was up to 83%. Out of 13 TCC patients, CK20 expression was
found in nine patients who were previously diagnosed by biopsy
and had a negative biopsy following treatment. These nine
patients were followed up for 6 months, and TCC recurred in four
patients.
Interpretation: Quantitative detection of CK20 in exfoliated cells
of urine is a simple and non-invasive method for monitoring and
follow-up of TCC in patients with bladder cancer. However, more
information is needed regarding CK20 expression in non-malig-
nant urological diseases to use it as amarker for routine screening.
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Background: Anthracycline-based neoadjuvant chemotherapy
kills cancer cells by inducing DNA double-strand breaks. In-
vitro studies have shown that DNA damage leads to localised
DNA methylation on CpG-rich sites found in promoter
regions. Promoter methylation of some tumour-suppressor
genes has been associated with poor prognosis. To determine
whether neoadjuvant chemotherapy induces promoter methyl-
ation, we evaluated the promoter regions of the SFRP1 and
CDH1 genes in locally advanced breast cancer, before and
after treatment.
Methods: Paired FFPE blocks of 61 patients with locally
advanced breast cancer before and after chemotherapy were col-
lected and confirmed by pathologists. Patients had standard fluo-
rouracil, doxorubicin (adriamycin), and cyclophosphamide (FAC)
chemotherapy for three cycles. In a subset of 12 patients, epige-
netic therapy (hydralazine and magnesium valproate) was added.
DNA isolation and bisulfite conversion were performed to evalu-
ate promoter methylation of SFRP1 and CDH1 genes using
methyl-specific PCR (MSP).
Findings: Using SFRP1 and CDH1 as surrogate markers, 13 of 41
(32%) and 18 of 48 (38%) patients showed induction of promoter
hypermethylation after chemotherapy (p = 0.052 and p = 0.012,
McNemar test). However, the rate of demethylation of both mark-
ers was 10%. To explore the reversibility of chemotherapy-
induced promoter hypermethylation, a subset of 12 patients were
treated with a combination of epigenetic therapy and chemother-
apy. Two of 12 patients (17%) showed hypermethylation and four
of 12 (33%) had an increased rate of promoter demethylation. The
dynamic status of promoter methylation is not associated with
hormone-receptor status, HER2 expression, age, or stage.
Interpretation: Neoadjuvant chemotherapy can induce pro-
moter methylation of tumour suppressor genes in a significant
proportion of patients, which may affect long-term clinical out-
come. This trend of promoter hypermethylation of tumour-sup-
pressor genes can be reversed using epigenetic therapy.
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Background: To determine the recommended dose and dose-
limiting toxicity (DLT) of epirubicin, oxaliplatin, and S-1 (EOS)
combination in patients with previously untreated advanced gas-
tric cancer (AGC).
Methods: Previously untreated patients with histologically pro-
ven metastatic or recurrent AGC and ECOG performance status 0–
2 were enrolled. A fixed dose of epirubicin (50 mg/m2) and oxalipl-
atin (130 mg/m2) was administered intravenously on day 1. The
dose of S-1 was escalated as follows: level 1, 30 mg/m2; level 2,
40 mg/m2; level 3, 45 mg/m2; level 4, 50 mg/m2. S-1 was adminis-
tered orally twice a day on days 1–14. Each cycle was repeated
every 21 days. DLTs were evaluated during the first two cycles
of treatment.
Findings: 19 patients were enrolled: 13 patients in the dose-
escalation phase and six patients in the extension at the recom-
mended dose. The median age was 53 years (range, 40–71 years).
At dose level 2, one DLToccured among six patients (grade 4 neu-
tropenia lasting more than 5 days), and at dose level 3, two DLTs
were observed among four patients (grade 3 diarrhoea and nau-
sea). Therefore, dose level 2 was determined to be the recom-
mended dose. Cumulative (all cycles) grade 3–4 toxicity included
neutropenia (58%), leucopenia (32%), thrombocytopenia (11%),
diarrhoea (11%), and nausea (5%). Of 13 patients with measurable
lesions, eight achieved a partial response and three had stable
disease, and the objective response rate was 62% (95% CI 36–
88%). Median progression-free survival was 6.5 months (4.7–8.2).
Interpretation The recommended dose of the EOS regimen in
patients with previously untreated AGC was epirubicin 50 mg/
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